Inventiva S.A.
- IVA
- NASDAQ
- Biotechnology
- Oral Small Molecule Therapies
- NASH Treatment
- MPS Therapeutics
$2.98
Today +1.36%Quote Oct 19, 2026, 08:00 PM UTC
−21.16%over the last month
Max drawdown −24.1%From 1-month high −21.2%3 months −33.5%
Our viewPro
The call stays with Pro
Verdict, why now, and the write-up open with Pro. New accounts get 14 days of Pro free.
About Inventiva
Inventiva S.A. is a biopharmaceutical company currently in its clinical development phase, specializing in the creation of orally administered small molecule therapeutics. The firm primarily targets serious conditions such as non-alcoholic steatohepatitis (NASH), various forms of mucopolysaccharidoses (MPS), and other significant diseases.
Sector
Healthcare
Industry
Biotechnology
Exchange
NASDAQ
Employees
77
Market value
$575.8M
Quote Oct 19
Analyst target
$14.00
+369.8% from here
Floor
$2.83
4.9% below price
Resistance
$3.01
1.0% above price
The call stays with Pro
7 locked chapters- What to do with this namePro
- Why nowPro
- Why this stockPro
- Section write-upsPro
- Story timelinePro
- News briefPro
- Ask about IVAPro
Verdict, why now, and the write-up open with Pro. New accounts get 14 days of Pro free.
Log in — 14 days free